• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BioPlus Acquisition Corp. (Amendment)

    2/7/24 2:00:23 PM ET
    $BIOS
    Blank Checks
    Finance
    Get the next $BIOS alert in real time by email
    SC 13G/A 1 formsc13ga.htm FORM SC 13G/A Saba Capital Management, L.P.: Form SC 13G/A - Filed by newsfilecorp.com

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

    BioPlus Acquisition Corp

    (Name of Issuer)

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

    G11217117

    (CUSIP Number)

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     [_]  Rule 13d-1(b)

     [X]  Rule 13d-1(c)

     [_]  Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    SCHEDULE 13G/A

    CUSIP No.           G11217117


    1 Names of Reporting Persons
    Saba Capital Management, L.P.
    2 Check the appropriate box if a member of a Group (see instructions)
    (a)  [ ]
    (b)  [ ]
    3 Sec Use Only
     
    4 Citizenship or Place of Organization
    Delaware
    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With:
    5 Sole Voting Power
    -0-
    6 Shared Voting Power
    -0-
    7 Sole Dispositive Power
    -0-
    8 Shared Dispositive Power
    -0-
    9 Aggregate Amount Beneficially Owned by Each Reporting Person
    -0-
    10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
    [ ]
    11 Percent of class represented by amount in row (9)
    0%
    12 Type of Reporting Person (See Instructions)
    PN; IA
           

    Page 2 of 7


    SCHEDULE 13G/A

    CUSIP No.           G11217117


    1 Names of Reporting Persons
    Boaz R. Weinstein
    2 Check the appropriate box if a member of a Group (see instructions)
    (a)  [ ]
    (b)  [ ]
    3 Sec Use Only
     
    4 Citizenship or Place of Organization
    United States
    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With:
    5 Sole Voting Power
    -0-
    6 Shared Voting Power
    -0-
    7 Sole Dispositive Power
    -0-
    8 Shared Dispositive Power
    -0-
    9 Aggregate Amount Beneficially Owned by Each Reporting Person
    -0-
    10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
    [ ]
    11 Percent of class represented by amount in row (9)
    0%
    12 Type of Reporting Person (See Instructions)
    IN
           

    Page 3 of 7


    SCHEDULE 13G/A

    CUSIP No.           G11217117


    1 Names of Reporting Persons
    Saba Capital Management GP, LLC
    2 Check the appropriate box if a member of a Group (see instructions)
    (a)  [ ]
    (b)  [ ]
    3 Sec Use Only
     
    4 Citizenship or Place of Organization
    Delaware
    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With:
    5 Sole Voting Power
    -0-
    6 Shared Voting Power
    -0-
    7 Sole Dispositive Power
    -0-
    8 Shared Dispositive Power
    -0-
    9 Aggregate Amount Beneficially Owned by Each Reporting Person
    -0-
    10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
    [ ]
    11 Percent of class represented by amount in row (9)
    0%
    12 Type of Reporting Person (See Instructions)
    OO
           

    Page 4 of 7


    Item 1.

    (a) Name of Issuer: BioPlus Acquisition Corp

    (b) Address of Issuer's Principal Executive Offices: 260 Madison Ave, Suite 800, New York, NY 10016

    Item 2.

    (a) Name of Person Filing: Saba Capital Management, L.P., a Delaware limited partnership ("Saba Capital"), Saba Capital Management GP, LLC, a Delaware limited liability company ("Saba GP"), and Mr. Boaz R. Weinstein (together, the "Reporting Persons").  The Reporting Persons have entered into a Joint Filing Agreement, dated December 13, 2021, pursuant to which the Reporting Persons have agreed to file this statement and any subsequent amendments hereto jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.  Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.  The filing of this statement should not be construed as an admission that any of the forgoing persons or the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the Common Stock reported herein.

    (b) Address of Principal Business Office or, if None, Residence:  The address of the business office of each of the Reporting Persons is 405 Lexington Avenue, 58th Floor, New York, New York 10174.

    (c) Citizenship: Saba Capital is organized as a limited partnership under the laws of the State of Delaware. Saba GP is organized as a limited liability company under the laws of the State of Delaware. Mr. Weinstein is a citizen of the United States.

    (d) Title and Class of Securities: Common stock, $0.0001 Par Value (the "Common Stock").

    (e) CUSIP No.: G11217117

    Item 3.  If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    (a) [_] Broker or dealer registered under Section 15 of the Act;

    (b) [_] Bank as defined in Section 3(a)(6) of the Act;

    (c) [_] Insurance company as defined in Section 3(a)(19) of the Act;

    (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940;

    (e) [_] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

    (f) [_] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

    (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

    (h) [_] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

    (j) [_] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);

    Page 5 of 7


    (k) [_] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

    Item 4. Ownership

    (a) Amount Beneficially Owned:  The information required by Items 4(a) - (c) is set forth in Rows (5) - (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

    Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X]

    Item 6. Ownership of more than Five Percent on Behalf of Another Person.  N/A

    Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person. N/A

    Item 8. Identification and classification of members of the group. N/A

    Item 9. Notice of Dissolution of Group.  N/A

    Item 10. Certifications.

    By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Page 6 of 7


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated:  February 7, 2024

    /s/ Signature  Michael D'Angelo

    Name: Michael D'Angelo

    Title: Chief Compliance Officer

    Boaz R. Weinstein

    By: Michael D'Angelo

    Title: Attorney-in-fact***

    *** Pursuant to a Power of Attorney dated as of November 16, 2015

    Page 7 of 7


    Get the next $BIOS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIOS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BIOS
    Financials

    Live finance-specific insights

    See more
    • Purple Innovation Announces Cooperative Framework with Coliseum Capital

      Company to Welcome New Directors to Board Adam Gray to Serve as Board Chair Gary DiCamillo to Continue to Serve as Lead Independent Director Company Will Redeem Cumulative Voting Proportional Representation Preferred Linked Stock Purple Innovation, Inc. (NASDAQ:PRPL) ("Purple" or the "Company"), a comfort innovation company known for creating the "World's First No Pressure® Mattress," today announced that it has entered into a binding Memorandum of Understanding to establish a cooperative governance framework (the "Planned Cooperation Agreement") with Coliseum Capital Management, LLC (together with its managed funds and accounts, "Coliseum"), the largest stockholder of the Company o

      4/13/23 4:05:00 PM ET
      $ADES
      $BIOS
      $LAZY
      $LOGI
      Major Chemicals
      Industrials
      Blank Checks
      Finance

    $BIOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by BioPlus Acquisition Corp. (Amendment)

      SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)

      2/12/24 4:14:06 PM ET
      $BIOS
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by BioPlus Acquisition Corp. (Amendment)

      SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)

      2/9/24 10:26:34 AM ET
      $BIOS
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by BioPlus Acquisition Corp. (Amendment)

      SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)

      2/7/24 2:00:23 PM ET
      $BIOS
      Blank Checks
      Finance

    $BIOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Bioplus Sponsor Llc

      4 - BioPlus Acquisition Corp. (0001856653) (Issuer)

      6/12/23 9:17:36 PM ET
      $BIOS
      Blank Checks
      Finance

    $BIOS
    SEC Filings

    See more
    • SEC Form 15-12G filed by BioPlus Acquisition Corp.

      15-12G - BioPlus Acquisition Corp. (0001856653) (Filer)

      10/16/23 4:15:07 PM ET
      $BIOS
      Blank Checks
      Finance
    • SEC Form 25-NSE filed by BioPlus Acquisition Corp.

      25-NSE - BioPlus Acquisition Corp. (0001856653) (Subject)

      10/6/23 4:03:10 PM ET
      $BIOS
      Blank Checks
      Finance
    • SEC Form RW filed by BioPlus Acquisition Corp.

      RW - BioPlus Acquisition Corp. (0001856653) (Filer)

      10/4/23 7:39:57 AM ET
      $BIOS
      Blank Checks
      Finance

    $BIOS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioPlus Acquisition Corp. Announces Termination of Business Combination Agreement with Avertix Medical, Inc. and its Intention to Liquidate

      New York, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BioPlus Acquisition Corp. ("BIOS" or the "Company") (NASDAQ:BIOS) announced today that (i) BIOS, Avertix Medical, Inc. and certain other parties have mutually agreed to terminate their previously announced business combination agreement and plan of reorganization (the "Business Combination Agreement"), effective as of October 4, 2023 and (ii) it intends to liquidate as soon as practicable after October 4, 2023 and to return funds to holders of its Class A ordinary shares that were included in the units issued in the Company's initial public offering ("Public Shares"). The Business Combination Agreement was dated as of May 2, 2023. The pa

      10/4/23 7:30:00 AM ET
      $BIOS
      Blank Checks
      Finance
    • Avertix and BIOS Acquisition Corporation Mutually Agree to Terminate Proposed Business Combination

      EATONTOWN, N.J. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. ("Avertix" or the "Company"), formerly known as Angel Medical Systems, Inc., a company focused on improving long-term management and outcomes of high-risk coronary disease in patients who have survived one or more heart attacks, and BIOS Acquisition Corporation (dba BioPlus Acquisition Corp.) ("BIOS") (NASDAQ:BIOS), a special purpose acquisition company, announced today that the two companies have mutually agreed to terminate their proposed business combination. "While we were enthusiastic about the potential business combination with BIOS, we mutually agreed that the current market conditions are not co

      10/4/23 7:30:00 AM ET
      $BIOS
      Blank Checks
      Finance
    • Carbonhand is available for Veterans in the US

      Bioservo signs a Sales Agent agreement with Trivet Medical LLC for sales of Carbonhand to Hospitals, Clinics, and Medical Centers within the Veterans Health Administration and Department of Defense in the US. With the first Sales Agent in place, the grip-strengthening device Carbonhand is available for all US Veterans suffering from impaired hand function. KISTA, Sweden, Aug. 29, 2023 /PRNewswire/ -- Trivet Medical LLC is a specialized strategic sales and distribution LLC, highly focused on commercializing disruptive, best-in-class med-tech devices and technologies. Founded by Charles Coyle, Trivet Medical's mission is to develop underrepresented and underserved healthcare conditions through

      8/29/23 3:03:00 AM ET
      $BIOS
      Blank Checks
      Finance